Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001 Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Aideen Ryan; EVA ERZSEBET SZEGEZDI

doi:10.1182/blood-2021-145530

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001 Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

Original language	English (Ireland)
Number of pages	0
Journal	Blood
Volume	138
Issue number	Supplement 1
DOIs	https://doi.org/10.1182/blood-2021-145530
Publication status	Published - 1 Nov 2021

Authors (Note for portal: view the doc link for the full list of authors)

Authors
Dawn Swan and Michael E. O\textquotesingleDwyer and Mary Cahill and Janusz Krawczyk and Vitaliy Mykytiv and John Quinn and Robert Henderson and Cian McEllistrim and Andres Hernando and Imelda Parker and Marc Nolan and Elizabeth Lenihan and Eva Szegezdi and Serika D Naicker and Kevin Lynch and Alessandro Natoni and Aideen Ryan and Philip Murphy

Access to Document

10.1182/blood-2021-145530

Cite this

@article{5a1bb1854e4045108e05fc1dabbe0c28,

title = "Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001 Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment",

author = "Aideen Ryan and SZEGEZDI, \{EVA ERZSEBET\}",

year = "2021",

month = nov,

day = "1",

doi = "10.1182/blood-2021-145530",

language = "English (Ireland)",

volume = "138",

journal = "Blood",

number = "Supplement 1",

}

TY - JOUR

T1 - Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001 Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

AU - Ryan, Aideen

AU - SZEGEZDI, EVA ERZSEBET

PY - 2021/11/1

Y1 - 2021/11/1

U2 - 10.1182/blood-2021-145530

DO - 10.1182/blood-2021-145530

M3 - Article

VL - 138

JO - Blood

JF - Blood

IS - Supplement 1

ER -